恒瑞医药九款药物临床试验获批

Core Viewpoint - Heng Rui Medicine announced the approval of multiple clinical trial applications for new drugs by the National Medical Products Administration, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries received approval for clinical trials of several injectable drugs, including SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642, and others [1] - A specific focus is on the Phase I/II study of SHR-9839(sc) in combination with anti-tumor drugs for safety, tolerability, and efficacy in solid tumor patients [1]